Cases & Deals

Avanir licenses D-DM from Concert for neurological disorders

Clients Avanir Pharmaceuticals, Inc.

Jones Day represented Avanir Pharmaceuticals, Inc. in its worldwide, exclusive license from Concert Pharmaceuticals to develop and commercialize deuterium-modified dextromethorphan for the potential treatment of neurological and psychiatric disorders. Concert will receive upfront payment and is eligible to receive milestone payments and royalties.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.